The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
YBX1 as an oncogenic factor in T-cell acute lymphoblastic leukemia
Open accessAbstract
Y-box-binding protein 1 (YBX1), a member of the RNA-binding protein family, is a critical regulator of cell survival in various solid tumors and acute myeloid leukemia. However, the function of YBX1 in T-cell acute lymphoblastic leukemia (T-ALL) remains elusive. Here, we found that YBX1 was upregulated in patients with T-ALL, T-ALL cell lines, and NOTCH1-induced T-ALL mice. Furthermore, depletion of YBX1 dramatically reduced cell proliferation, induced cell apoptosis, and induced G0/G1 phase arrest in vitro. Moreover, YBX1 depletion significantly decreased the leukemia burden in the human T-ALL xenograft and NOTCH1-induced T-ALL mice model in vivo. Mechanistically, downregulation of YBX1 markedly inhibited the expression of total AKT serine/threonine kinase (AKT), p-AKT, total extracellular signal-regulated kinase (ERK), and p-ERK in T-ALL cells. Taken together, our results uncovered a critical role of YBX1 in the leukemogenesis of T-ALL, which may have great potential as a biomarker and therapeutic target in T-ALL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“YBX1 is an oncogenic pro-survival factor in leukemia”
From Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia (2024) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Su, H., Fan, G., Huang, J., & Qiu, X. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110049 · Cited by 31
RetractedEndogenous tRNA-Derived Fragments Suppress Breast Cancer Progression via YBX1 Displacement
Goodarzi, H., Liu, X., Nguyen, H. C. B., Zhang, S., Fish, L., & Tavazoie, S. F. (2015) · Cell · doi:10.1016/j.cell.2015.02.053 · Cited by 949
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia
Liu, Y., Easton, J., Shao, Y., Maciaszek, J., Wang, Z., Wilkinson, M. R., McCastlain, K., Edmonson, M., Pounds, S. B., Shi, L., et al. (2017) · Nature Genetics · doi:10.1038/ng.3909 · Cited by 918
Self-citationClaesson‐Welsh, L., & Welsh, M. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12019 · Cited by 868
5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs
Chen, X., Li, A., Sun, B.-F., Yang, Y., Han, Y.-N., Yuan, X., Chen, R.-X., Wei, W.-S., Liu, Y., Gao, C.-C., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0361-y · Cited by 801
Self-citationFGF Receptors: Cancer Biology and Therapeutics: CANCER BIOLOGY AND THERAPEUTICS ON FGF RECEPTORS
Katoh, M., & Nakagama, H. (2014) · Medicinal Research Reviews · doi:10.1002/med.21288 · Cited by 610
The pleiotropic functions of the Y‐box‐binding protein, YB‐1
Kohno, K., Izumi, H., Uchiumi, T., Ashizuka, M., & Kuwano, M. (2003) · BioEssays · doi:10.1002/bies.10300 · Cited by 502
CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1
Xu, J., Ji, L., Liang, Y., Wan, Z., Zheng, W., Song, X., Gorshkov, K., Sun, Q., Lin, H., Zheng, X., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00375-5 · Cited by 495
Möricke, A., Zimmermann, M., Valsecchi, M. G., Stanulla, M., Biondi, A., Mann, G., Locatelli, F., Cazzaniga, G., Niggli, F., Aricò, M., et al. (2016) · Blood · doi:10.1182/blood-2015-09-670729 · Cited by 283
Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis
El-Naggar, A. M., Veinotte, C. J., Cheng, H., Grunewald, T. G. P., Negri, G. L., Somasekharan, S. P., Corkery, D. P., Tirode, F., Mathers, J., Khan, D., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.003 · Cited by 283
Cited by
Dinh, N. T. M., Nguyen, T. M., Park, M. K., & Lee, C. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020717 · Cited by 63
o8G-modified circKIAA1797 promotes lung cancer development by inhibiting cuproptosis
Xu, H., Zhao, Q., Cai, D., Chen, X., Zhou, X., Gao, Y., Wu, J., Yuan, S., Li, D., Zhang, R., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03365-z · Cited by 27
Self-citationDevelopment of an efficient, effective, and economical technology for proteome analysis
Martin, K. R., Le, H. T., Abdelgawad, A., Yang, C., Lu, G., Keffer, J. L., Zhang, X., Zhuang, Z., Asare‐Okai, P. N., Chan, C. S., et al. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100796 · Cited by 29
Self-citationYBX1: an RNA/DNA-binding protein that affects disease progression
Zheng, X., Zeng, F., Lei, Y., Li, Y., Deng, J., Luo, G., He, Q., & Zhou, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1635209 · Cited by 22
Adnan Awad, S., Dufva, O., Klievink, J., Karjalainen, E., Ianevski, A., Pietarinen, P., Kim, D., Potdar, S., Wolf, M., Lotfi, K., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101521 · Cited by 14
“…the TKI-sensitization ef-fectof IGF1R KO, IGF1R inhibitors werereportedtoovercomeTKI resistance in CML. 52 YBX1 is an oncogenic pro-survival factor in leukemia, 53,54 and therefore, YBX1 depletion is expected to enhance dasatinib killing through impairment of the DNA damage response in CML cells.”
Metadata
- Authors
- Li, H., Zhang, D., Fu, Q., Wang, S., Wang, Z., Zhang, X., Chen, X., Zhu, X., An, N., Chen, Y., Zhou, L., Lu, D., & Zhao, N.
- Affiliations
- Shenzhen University (CN)
- Chongqing Medical University (CN)
- University of Science and Technology of China (CN)
- Nanjing Medical University (CN)
- Corresponding author
- Zhao, Na
- ORCID
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2023-08-24
- Volume
- 7
- Issue
- 17
- Pages
- 4874-4885
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- PMC
- PMC10469076
- OpenAlex
- W4381432683
- Cited by
- 21
- References
- 44
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 7 · 2023: 1
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Blood Advances (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (31970739)
- Topics
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- YB-1, T-cell acute lymphoblastic leukemia, RNA-binding proteins, oncogenic factor, Notch1, Akt signaling, ERK signaling, cell proliferation, apoptosis, G0/G1 cell cycle arrest, leukemogenesis, therapeutic target, biomarkers
- MeSH terms
- Animals, Humans, T-Lymphocytes, Signal Transduction, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, Mice, Y-Box-Binding Protein 1, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: YBX1 as an oncogenic factor in T-cell acute lymphoblastic leukemia. https://app.cochat.ai/papers/10.1182/bloodadvances.2022009648
- The paper
- Li, H., Zhang, D., Fu, Q., Wang, S., Wang, Z., Zhang, X., Chen, X., Zhu, X., An, N., Chen, Y., Zhou, L., Lu, D., & Zhao, N. (2023). YBX1 as an oncogenic factor in T-cell acute lymphoblastic leukemia. Blood Advances. https://doi.org/10.1182/bloodadvances.2022009648
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.